Wie viel ist die Pharmaindustrie im Jahr 2025 wert?

The pharmaceutical industry keeps expanding, both in value and global reach. New drugs, aging populations, and rising health needs are pushing demand higher each year. 

In this article, we’ll examine the industry’s worth in 2025 and the factors driving that growth.

Pharmaceutical Industry Worth in 2025 (and What’s Driving It)

The global pharmaceutical industry is projected to generate $1.21 trillion in revenue in 2025, according to Statista. The U.S. alone is expected to account for more than half of that total, reaching $660.04 billion, thanks to its advanced healthcare systems and strong R&D investment.

Among therapeutic areas, oncology remains the top revenue generator, with a market value projected at $208.86 billion in 2025, growing 7.6% year-over-year (Becker’s Hospital Review). Other high-performing segments include:

• Anti-diabetes drugs: $84.48 billion (8.3% growth)
• Immunosuppressants: $61.05 billion (15.1% growth)
• Antiviral drugs: $52.19 billion (2% growth)

Looking further ahead, Statista forecasts a compound annual growth rate (CAGR) of 4.77% from 2025 to 2029, pushing total industry revenue to $1.45 trillion by 2029.

GLP-1 drugs, used for treating Type 2 diabetes and obesity, are also a major factor in current growth. Sales of these drugs topped $1 billion in 2024 and are expected to keep rising in 2025, with companies like Novo Nordisk and Eli Lilly expanding their production capacity to meet global demand (Investing News Network).

The steady increase in market size reflects global demand for chronic disease treatments, innovation in biotech and specialty drugs, and broader healthcare access in emerging markets.

Top Segments Fueling Market Growth

Several fast-moving segments are driving the pharmaceutical industry’s growth in 2025. These areas are attracting the most investment and shaping the future of drug development.

Gene and cell therapies are becoming major players in the market. These treatments target once untreatable diseases, offering new hope and high revenue potential.

• The cell therapy market is projected to hit $87.22 billion by 2026
• Gene therapy is expected to reach $13.25 billion in the same period

Bispecific antibodies are another breakthrough area. These next-gen treatments are showing strong trial results in blood cancers and lung cancer.

• Ivonescimab, developed by Akeso Biopharma, outperformed Keytruda in survival rates
• Arcus Biosciences’ domvanalimab showed a 36% reduction in the risk of death in a lung cancer trial

Digital therapeutics and telehealth are expanding how patients access medications. Companies are adapting to online platforms to reach more people.

• Eli Lilly partnered with Ro to offer GLP-1 medications via telehealth
• These models reduce cost barriers and increase direct-to-patient access

Immunology continues to grow through innovation. New biologics and targeted therapies are replacing aging blockbuster drugs.

• AbbVie’s new immunology drugs are offsetting declines in older treatments like Humira

These high-growth segments are reshaping the industry, moving it toward more precise, tech-enabled, and personalized treatments.

What This Means for Pharma Manufacturers and Suppliers

Rising market value, demand for advanced therapies, and a push toward personalized medicine are opening new opportunities—but also raising the bar for manufacturers and suppliers.

Pharma companies are under pressure to scale faster, launch more complex products, and meet tighter compliance standards. This means production lines need to be more flexible, efficient, and GMP-compliant.

For machinery suppliers and production partners, the message is clear:

• Speed and accuracy matter more than ever
• Equipment must support diverse formulations—from traditional powders to sensitive biologics
• Systems need to scale easily as demand grows
• Integration with quality control and digital monitoring tools is becoming a must

Canaan supports this shift by providing reliable, high-performance machinery that helps pharma companies stay competitive. From capsule filling to automated packaging, our systems are built for the demands of today’s pharmaceutical production.

How Much Is the Pharmaceutical Industry Worth: Conclusion

The pharmaceutical industry’s growth in 2025 isn’t just about numbers—it reflects a global shift in how healthcare is delivered, accessed, and advanced. For manufacturers and suppliers, this means moving quickly, investing wisely, and staying aligned with regulatory and market demands. The winners in this space will be those who combine quality, efficiency, and the ability to adapt.

Canaan is here to support that journey—with machinery Und Lösungen built for what’s next in pharma.